HB3561 would amend the Illinois Insurance Code to require most group and individual accident and health insurance policies, as well as managed care plans, to cover at least one early egg allergen introduction dietary supplement and at least one early peanut allergen introduction dietary supplement. The bill defines these products as infant-prescribed supplements containing sufficient egg or peanut protein to help reduce the risk of food allergies, and it requires that the coverage be provided at no cost to the enrollee, including after a deductible is met, subject to certain federal-law exceptions.
The mandate would apply to policies and plans issued, delivered, amended, or renewed on or after January 1, 2027. It excludes several limited-benefit products, including accident-only, specified disease, hospital indemnity, Medicare supplement, long-term care, and disability income policies. It also includes safeguards so the new cost-sharing rule does not interfere with catastrophic health plan status, high-deductible health plan status, or health savings account eligibility under federal law. The bill further amends multiple public and employer coverage statutes so the same benefit applies across state employee plans, county and municipal self-insurance, school employee coverage, HMOs, limited health service organizations, voluntary health services plans, and Medicaid.
In practical terms, the bill would expand Illinois insurance mandates by adding a new preventive infant nutrition benefit tied to allergy prevention. It would require insurers, HMOs, public employee plans, and Medicaid to treat these supplements as covered health benefits, and it assigns enforcement to the Department of Insurance for some provisions and the Department of Central Management Services for others. The measure would therefore affect insurers, public employers, managed care organizations, and families seeking early allergy-prevention products for infants.
Because there are no committee transcripts or recorded votes provided, there is no documented legislative debate or voting pattern to gauge formal sentiment. Based on the bill text alone, the measure appears to be framed as a public-health and preventive-care expansion, with a clear consumer-protection emphasis through zero-cost coverage. The absence of recorded opposition or amendments in the provided materials means no specific support or resistance can be identified from the available history.
The main potential points of contention are likely to involve insurance-mandate costs, the scope of required coverage, and interactions with federal benefit rules. The bill anticipates some of these concerns by carving out limited-benefit policies and preserving catastrophic plan and HSA compatibility, but insurers or employers could still object to added premium costs or administrative complexity. Supporters would likely focus on allergy prevention and infant health benefits, while skeptics may question whether a state coverage mandate is the best mechanism for promoting early allergen introduction.
HB3561 would add a new mandated health benefit to Illinois insurance law and extend that mandate across multiple state-regulated coverage systems, including private insurance, HMOs, public employee plans, and Medicaid. It would create Section 356z.80 of the Illinois Insurance Code and conforming amendments in the State Employees Group Insurance Act, Counties Code, Illinois Municipal Code, School Code, Health Maintenance Organization Act, Limited Health Service Organization Act, Voluntary Health Services Plans Act, and Illinois Public Aid Code. The bill would require coverage for early egg and peanut allergen introduction dietary supplements beginning with policies renewed or issued on or after January 1, 2027, while preserving certain federal-law protections for catastrophic and high-deductible plans.
No committee testimony or vote history was provided, so there is no recorded legislative sentiment to summarize from debate or roll calls. From the bill text, the measure is presented in a strongly supportive, preventive-health frame, suggesting a policy goal of reducing childhood food allergies through insurance coverage. The structure of the bill also shows an effort to address likely implementation concerns by including federal-law exceptions and excluding limited-benefit products.
The most likely points of contention are cost, mandate breadth, and federal compatibility. Insurers and employers may object to requiring no-cost coverage for a new category of infant dietary supplements, especially because the bill applies broadly across private and public plans. Another possible concern is whether the supplements should be covered as a medical benefit at all, versus being treated as a consumer product or nutritional item. The bill attempts to limit these objections by exempting certain policy types and preserving high-deductible health plan and HSA treatment, but those carveouts also indicate where implementation issues could arise.